Overview

Trans-catheter Arterial Embolization Combined With p53 Gene Therapy for Treatment of Advanced Hepatocellular Carcinoma

Status:
Unknown status
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
An open-labeled, randomized, active-controlled phase II study to investigate clinical efficacy and immunoreaction using trans-catheter arterial embolization (TAE) combined with p53 gene therapy in treatment of advanced hepatocellular carcinoma (HCC).
Phase:
Phase 2
Details
Lead Sponsor:
Shenzhen SiBiono GeneTech Co.,Ltd